Nengming Lin

1.2k total citations
55 papers, 870 citations indexed

About

Nengming Lin is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Nengming Lin has authored 55 papers receiving a total of 870 indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Molecular Biology, 19 papers in Oncology and 13 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Nengming Lin's work include Ubiquitin and proteasome pathways (9 papers), Lung Cancer Treatments and Mutations (7 papers) and Lung Cancer Research Studies (7 papers). Nengming Lin is often cited by papers focused on Ubiquitin and proteasome pathways (9 papers), Lung Cancer Treatments and Mutations (7 papers) and Lung Cancer Research Studies (7 papers). Nengming Lin collaborates with scholars based in China, Macao and New Zealand. Nengming Lin's co-authors include Chong Zhang, Lin‐wen Wu, Biqin Tan, Qiaojun He, Bo Zhang, Yang-ling Li, Youyou Yan, Hong Zhu, Linghui Zeng and Bo Yang and has published in prestigious journals such as SHILAP Revista de lepidopterología, Cancer Research and Oncogene.

In The Last Decade

Nengming Lin

51 papers receiving 862 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nengming Lin China 19 569 221 180 173 72 55 870
Zhilin Zou China 10 560 1.0× 227 1.0× 133 0.7× 222 1.3× 64 0.9× 24 901
Haijun Zhang China 15 544 1.0× 211 1.0× 154 0.9× 229 1.3× 75 1.0× 24 870
Virginie Poindessous France 17 484 0.9× 282 1.3× 123 0.7× 187 1.1× 61 0.8× 32 837
Nancy De Nève Belgium 17 490 0.9× 211 1.0× 114 0.6× 216 1.2× 90 1.3× 31 961
Xianping Shi China 20 683 1.2× 261 1.2× 111 0.6× 148 0.9× 48 0.7× 35 1.0k
Mihail Buse Romania 8 511 0.9× 180 0.8× 99 0.6× 176 1.0× 83 1.2× 14 878
Jing‐Wen Bai China 17 572 1.0× 308 1.4× 159 0.9× 269 1.6× 70 1.0× 39 1.0k
Peng Zou China 13 644 1.1× 208 0.9× 194 1.1× 256 1.5× 53 0.7× 25 1.1k
Haolan Wang China 6 520 0.9× 251 1.1× 124 0.7× 192 1.1× 61 0.8× 9 861
Guangchun He China 15 478 0.8× 323 1.5× 176 1.0× 297 1.7× 49 0.7× 25 952

Countries citing papers authored by Nengming Lin

Since Specialization
Citations

This map shows the geographic impact of Nengming Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nengming Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nengming Lin more than expected).

Fields of papers citing papers by Nengming Lin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nengming Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nengming Lin. The network helps show where Nengming Lin may publish in the future.

Co-authorship network of co-authors of Nengming Lin

This figure shows the co-authorship network connecting the top 25 collaborators of Nengming Lin. A scholar is included among the top collaborators of Nengming Lin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nengming Lin. Nengming Lin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Liu, Jinming, et al.. (2025). Ubiquitination regulation of mitochondrial homeostasis: a new sight for the treatment of gastrointestinal tumors. Frontiers in Immunology. 16. 1533007–1533007. 1 indexed citations
2.
Wang, Nan, Mingjian Zhu, Jiahe Wu, et al.. (2025). Dual-targeting pluripotential biomimetic nanovehicle modulates tumor immune microenvironment for potentiated cancer chemoimmunotherapy. Chemical Engineering Journal. 523. 167894–167894.
3.
Lu, Yang, Peipei Wang, Haifeng Chen, et al.. (2024). Discovery of potent small molecule ubiquitin-specific protease 10 inhibitors with anti-hepatocellular carcinoma activity through regulating YAP expression. European Journal of Medicinal Chemistry. 272. 116468–116468. 9 indexed citations
4.
5.
Li, Ping, et al.. (2024). SLC15A3 plays a crucial role in pulmonary fibrosis by regulating macrophage oxidative stress. Cell Death and Differentiation. 31(4). 417–430. 16 indexed citations
6.
Li, Qi, Qingyi Zhang, Daoming Zhang, et al.. (2024). Wee1 inhibitor PD0166285 sensitized TP53 mutant lung squamous cell carcinoma to cisplatin via STAT1. Cancer Cell International. 24(1). 315–315. 2 indexed citations
7.
Wang, Xiang, Xinxin Ren, Xu Lin, et al.. (2024). Recent progress of ferroptosis in cancers and drug discovery. Asian Journal of Pharmaceutical Sciences. 19(4). 100939–100939. 16 indexed citations
8.
Zhang, Jiankang, Zheng Wang, Jie Li, et al.. (2023). Triacanthine enhances the sensitivity of colorectal cancer cells to 5-fluorouracil by regulating RRM2. Phytomedicine. 126. 155204–155204.
9.
Peng, Yi, Yan Lou, Lijuan Cao, et al.. (2022). Downregulation of the farnesoid X receptor promotes colorectal tumorigenesis by facilitating enterotoxigenic Bacteroides fragilis colonization. Pharmacological Research. 177. 106101–106101. 25 indexed citations
10.
Li, Yang-ling, Man-man Zhang, Lin‐wen Wu, et al.. (2022). DYRK1A reinforces epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma via cooperatively activating STAT3 and SMAD. Journal of Biomedical Science. 29(1). 34–34. 12 indexed citations
11.
Li, Yang-ling, et al.. (2020). ApoC1 promotes the metastasis of clear cell renal cell carcinoma via activation of STAT3. Oncogene. 39(39). 6203–6217. 65 indexed citations
12.
Dong, Rong, Bo Zhang, Biqin Tan, & Nengming Lin. (2020). Long non-coding RNAs as the regulators and targets of macrophage M2 polarization. Life Sciences. 266. 118895–118895. 16 indexed citations
13.
Li, Yangling, Dongmei Zhou, Shuang Xu, et al.. (2020). DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors. Cancer Biology and Medicine. 17(2). 387–400. 15 indexed citations
14.
Li, Yang-ling, Jiao Sun, Yiming Zhao, et al.. (2016). Evodiamine induces apoptosis and enhances apoptotic effects of erlotinib in wild-type EGFR NSCLC cells via S6K1-mediated Mcl-1 inhibition. Medical Oncology. 33(2). 16–16. 22 indexed citations
15.
Zhang, Dan, Bo Zhang, Lixin Zhou, et al.. (2016). Deacetylisovaltratum disrupts microtubule dynamics and causes G2/M-phase arrest in human gastric cancer cells in vitro. Acta Pharmacologica Sinica. 37(12). 1597–1605. 10 indexed citations
16.
Cao, Ji, Yijie Wang, Rong Dong, et al.. (2015). Hypoxia-Induced WSB1 Promotes the Metastatic Potential of Osteosarcoma Cells. Cancer Research. 75(22). 4839–4851. 57 indexed citations
17.
Ying, Meidan, Xinglu Zhou, Like Zhong, et al.. (2012). Bortezomib Sensitizes Human Acute Myeloid Leukemia Cells to All- Trans -Retinoic Acid–Induced Differentiation by Modifying the RARα/STAT1 Axis. Molecular Cancer Therapeutics. 12(2). 195–206. 36 indexed citations
18.
Zhang, Chong, Tianyu Cai, Hong Zhu, et al.. (2011). Synergistic Antitumor Activity of Gemcitabine and ABT-737 In Vitro and In Vivo through Disrupting the Interaction of USP9X and Mcl-1. Molecular Cancer Therapeutics. 10(7). 1264–1275. 46 indexed citations
19.
20.
Fan, Yun, Nengming Lin, Shenglin Ma, et al.. (2010). Phase II trial of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer. Acta Pharmacologica Sinica. 31(6). 746–752. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zhilin Zou Breakdown of academic impact, for papers by Haijun Zhang Breakdown of academic impact, for papers by Virginie Poindessous Breakdown of academic impact, for papers by Nancy De Nève Breakdown of academic impact, for papers by Xianping Shi Breakdown of academic impact, for papers by Mihail Buse Breakdown of academic impact, for papers by Jing‐Wen Bai Breakdown of academic impact, for papers by Peng Zou Breakdown of academic impact, for papers by Haolan Wang Breakdown of academic impact, for papers by Guangchun He
Rankless by CCL
2026